Cana­di­an biotech to dis­con­tin­ue omega-3 pro­gram af­ter sec­ond PhI­II fails on sig­nif­i­cant triglyc­eride re­duc­tion

It’s been an event­ful 12 months or so for the omega-3 mar­ket, but one com­pa­ny’s lat­est at­tempt to use the ap­proach for se­vere hy­per­triglyc­eridemia came up short.

Cana­di­an biotech Acasti Phar­ma $AC­ST re­port­ed a sec­ond Phase III flop for its omega-3 phos­pho­lipid can­di­date CaPre on Mon­day, as the tri­al did not reach sta­tis­ti­cal sig­nif­i­cance for its pri­ma­ry end­point. The com­pa­ny stat­ed that, as a re­sult, it will not file for an NDA in the US nor con­duct ad­di­tion­al tri­als for the pro­gram.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER